Recent studies have also investigated the ability of small therapeutic compounds using a custom chemical library to improve tau-induced rough-eye phenotype in a Drosophila melanogaster model of frontotemporal dementia (FTD) and showed that Ro 31-8220, a potent inhibitor of PKCα, improved the rough-eye phenotype, reduced phosphorylated Tau species in vitro and in vivo, reversed Tau-induced memory impairment, and improved the fly motor functions [150]. This evidence concerns the gene MAPT and memory impairment.